Bio Protocol, a decentralized science startup, has received $6.9 million in new investment to develop its artificial intelligence (AI) biotech research model.
Supporters include Maelstrom Fund and Animoca Brands, two groups known for backing tech-focused ventures.
Rather than following traditional academic or pharmaceutical routes, Bio Protocol is building a system that integrates AI tools, crypto infrastructure, and community participation. The goal is to speed up the research process, especially in areas like drug discovery.
Did you know?
Subscribe – We publish new crypto explainer videos every week!
What is Ethereum Classic & ETC Coin? (Animated Explainer)
Arthur Hayes, founder of Maelstrom Fund, sees Bio Protocol as more than just another research tool. He said the platform could lead to an entirely new kind of science marketplace.
At the center of Bio Protocol’s approach are “BioAgents”, automated tools that use AI to suggest experiments and manage on-chain activity. These agents can help raise funds directly from supporters, which allows researchers to begin projects without the lengthy wait for academic grants or industry partnerships.
All activities on the platform will be recorded on a blockchain to create a clear and permanent trail of who contributed what.
Additionally, the platform uses token-based systems. These include digital ownership of research, reward mechanisms for loyalty, and staking systems that align the goals of scientists, backers, and supporters.
Meanwhile, Helius Medical Technologies recently announced plans to build $500 million reserve of Solana. What did the company say? Read the full story.
